Faes Farma, S.a. · BME:FAE
Faes Farma — H1 2026 Earnings Presentation
20 slides from Faes Farma's earnings presentation, Jul 1, 2026
Slide 1: Report H1 2026 Faes Farma
aft FAES FARMA REPORT H1 2026 FAES FARMA
Slide 2: Index
Index 1/ 2/ 3/ Highlights and key Business H1 2026 figures performance Results
Slide 3: Highlights and key figures
1/ Highlights and key figures
Slide 4: Highlights – H1 2026
HIGHLIGHTS AND KEY FIGURES Highlights – H1 2026 Total revenue +27%. This growth was driven mainly by the integration of acquisitions and the strong performance of international markets, in both direct sales and licensing. Business Pharma revenue +28%, with the integration of ophthalmology as a key a
Slide 5: Key figures for S1 2026
HIGHLIGHTS AND KEY FIGURES Key figures for S1 2026 Revenue BAI 391.5 M€ 66.8 M€ 27% 8% EBITDA Net profit 90.8 M€ 57 M€ 24% 9% 5
Slide 6: Business performance S1 2026
2/ Business performance S1 2026
Slide 7: Revenue by portfolio segment
BUSINESS PERFORMANCE H1 2026 Revenue by portfolio segment Millions of € Millions of euros S1 2026 S1 2025 % Bilastine Pharma 340.6 266.3 28% Bilastine fell by -9%, mainly due to the expected expiry of patent protection in Japan. Pharma top 3 molecules 125.9 126.9 (1%) 74.8 Excluding this effect, the
Slide 8: Revenue by business area
BUSINESS PERFORMANCE H1 2026 Revenue by business area Milions of euros S1 2026 S1 2025 % Pharma 340.6 266.3 28% Animal Pharma Iberia 132.1 115.7 14% Nutrition and Pharma International (without licenses) 142.4 77.8 83% Health 12% Pharma Iberia Pharma Licenses 66.2 72.8 (9%) 34% Animal Nutrition and H
Slide 9: Farma Iberia
BUSINESS PERFORMANCE H1 2026 Farma Iberia Revenue H1 2026 SPAIN 0.2% €132.1 million 14% The prescription business showed stable performance during the first half of 2026, supported by above-market growth in calcifediol and the strengthening of the respiratory division’s market position. Bilastina re
Slide 10: International Pharmaceuticals
BUSINESS PERFORMANCE H1 2026 International Pharmaceuticals H1 2026 revenue LATAM 19% €142.4 million 83% Latin America has established itself as the company’s main area of organic growth. Most markets continue to record very significant growth: Mexico (+34 %), Colombia (+22 %), Central America (+20 %
Slide 11: Pharmaceutical Licences
BUSINESS PERFORMANCE H1 2026 Pharmaceutical Licences Revenue H1 2026 BILASTINE LICENCE -12% €66.2 million -9% Bilastine sales have declined following the expiry of patent protection in Japan, where generics have been launched, including our own generic version, thus marking the start of a new phase
Slide 12: Farm Faes
BUSINESS PERFORMANCE H1 2026 Farm Faes Revenue H1 2026 €46.5 million 21% FARM Faes 46,5 38,4 The first half of 2026 can be described as very positive. FARM Faes has maintained growth of 21%, confirming that the strategic focus on ISF and internationalisation is yielding results. H1 2025 H1 2026 This
Slide 13: H1 2026 Results
af FAES FARMA H1 2026
Slide 14: Income Statement H1 2026
H1 2026 RESULTS Income Statement H1 2026 % REVENUES Thousand € H1 2026 H1 2025 change The increase in revenue is due both to the contribution of the new scope of consolidation and to the solid growth of the companies Net turnover 382,897 296,162 29.3% that already form part of the Group, which under
Slide 15: Free cash flow
H1 2026 RESULTS Free cash flow WORKING CAPITAL A temporary increase in working capital resulting from the Free Cash Flow normalisation and operational integration of SIFI, the usual seasonality of the Licensing business (in line with previous financial Thousand € H1 2026 years), and the rise in stoc
Slide 16: Financial strength and a balanced debt profile
H1 2026 RESULTS Financial strength and a balanced debt profile Net debt evolution (€M) FCF: 18.9 267,5 FCO: 28.2 12,8 261,4 5,4 3,9 11,7 0,2 50,7 -90,8 Net debt /EBITDA* <2 DN EBITDA WC Capex Other Otros Impuestos Impuestos Interest Intereses Dividends Dividendos DN 26H1 Debt Maturities (€M) Liquidi
Slide 17: 2026 guidance reaffirmed following a strong half-year
2026 guidance reaffirmed following a strong half-year REVENUE 2026 EBITDA 2026* NET DEBT 2026 +17% / +19% +28% / +31% < 2x EBITDA vs €627 million, 2025 vs €118 million, 2025 Key growth drivers for 2026 ∕ Driving growth in strategic international markets, particularly Latin America, to offset the imp
Slide 18: Q&A
af FAES FARMA ofp ens FAT Q&A
Slide 19: Disclaimer
DISCLAIMER This presentation has been prepared and published by Faes Pharma Group for information purposes only. This presentation does not constitute a prospectus or an offer or recommendation to invest. This presentation does not constitute a commitment to subscribe, an offer of financing or an of
Slide 20: Appendix
H1 2026 H1 2025 Var % Iberia 132.1 115.7 14% Appendix Pharma Spain Prescription 95.9 62.0 95.7 63.7 0% -3% 10.6 12.8 -17% Split of revenue Bilastine RX Calcifediol 23.4 22.8 3% Mesalazine 3.5 3.5 -2% Other 24.6 24.6 -0% Healthcare & Consumer 33.9 31.9 6% Portugal Pharma 36.2 20.0 81% Faes Farma Port